Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | PNP | P00491 | 1/20 | 0.34 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21363641 | 0.81 | POLB (0.44) | POLBALDH1A1HPGDBRD4KDM4E | |
| SCHEMBL21353905 | 0.79 | POLB (0.43) | POLBALDH1A1HPGDBRD4KDM4E | |
| SCHEMBL21363637 | 0.79 | POLB (0.47) | POLBALDH1A1HPGDBRD4KDM4E | |
| SCHEMBL21393362 | 0.79 | POLB (0.43) | POLBALDH1A1HPGDBRD4KDM4E | |
| SCHEMBL21393574 | 0.77 | POLB (0.41) | POLBALDH1A1HPGDBRD4KDM4E | |
| SCHEMBL21393418 | 0.73 | SMN1; SMN2 (0.40) | POLBALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL13202761 | 0.72 | ADORA2A (0.51) | ALDH1A1HPGDPNPATAD2GAA | |
| SCHEMBL21393365 | 0.70 | CYP3A4 (0.40) | POLBALDH1A1KDM4EHSD17B10PNP | |
| SCHEMBL21367881 | 0.70 | ADORA2B (0.40) | POLBALDH1A1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL7990063 | 0.69 | ALDH1A1 (0.47) | POLBALDH1A1HPGDBRD4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768260-B1 | OXADIAZOLE COMPOUNDS AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2025-10-08 | — | — | EP | disclosed |
| US-20250122184-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-12202824-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| CN-110225911-A | Oxadiazolone transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2019-09-10 | — | — | CN | disclosed |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| EP-3389664-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | Raze Therapeutics Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
| WO-2017106352-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106352-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017060488-A1 | NEW TRPA1 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | POLB 1467/4885ALDH1A1 260/4885HPGD 188/4885 |
| US-12202824-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | POLB 4804/4885ALDH1A1 721/4885HPGD 816/4885 |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, P2RX3 | POLB 4798/4885ALDH1A1 665/4885HPGD 822/4885 |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | POLB 4583/4885ALDH1A1 319/4885HPGD 346/4885 |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | POLB 1467/4885ALDH1A1 260/4885HPGD 188/4885 |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | POLB 1467/4885ALDH1A1 260/4885HPGD 188/4885 |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | POLB 4804/4885ALDH1A1 721/4885HPGD 816/4885 |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | POLB 4804/4885ALDH1A1 721/4885HPGD 816/4885 |
| US-20250122184-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | POLB 4804/4885ALDH1A1 721/4885HPGD 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.